The content on this site is intended for healthcare professionals only
Dr Gluz talks to ecancertv at SABCS 2015 about biomarker driven clinical trials and the WSG-ADAPT TN randomised phase II trial.
WSG-ADAPT TN is an adjuvant dynamic marker-adjusted personalised therapy trial, optimising risk assessment and therapy response prediction in early breast cancer.
Breast and emerging indications for IORT
The advantages of IORT for early breast cancer treatment
The pros and cons of breast IORT and ultra hypofractionation (FR)
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Global adoption of single-shot targeted IORT for breast cancer
IORT at the Asian Hospital and Medical Center
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
The advancements in radiotherapy for breast cancer patients
